Difference between revisions of "Vandetanib (Caprelsa)"
m |
m |
||
| Line 1: | Line 1: | ||
| − | + | Also known as ZD6474. | |
==General information== | ==General information== | ||
Revision as of 18:52, 19 April 2012
Also known as ZD6474.
General information
Class/mechanism: Tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor), VEGF (vascular endothelial cell growth factor), RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Vandetanib (Caprelsa) patient drug information (Chemocare)[5]
- Vandetanib (Caprelsa) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
- ↑ Caprelsa manufacturer's website
- ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Vandetanib (Caprelsa) patient drug information (Chemocare)
- ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)